These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30453199)

  • 21. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
    Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron deposition in the gray matter in patients with relapse-remitting multiple sclerosis: A longitudinal study using three-dimensional (3D)-enhanced T2*-weighted angiography (ESWAN).
    Du S; Sah SK; Zeng C; Wang J; Liu Y; Xiong H; Li Y
    Eur J Radiol; 2015 Jul; 84(7):1325-32. PubMed ID: 25959392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
    Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron deposition and atrophy in cerebral grey matter and their possible association with serum iron in relapsing-remitting multiple sclerosis.
    Al-Radaideh A; El-Haj N; Hijjawi N
    Clin Imaging; 2021 Jan; 69():238-242. PubMed ID: 32977196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
    Gracien RM; Jurcoane A; Wagner M; Reitz SC; Mayer C; Volz S; Hof SM; Fleischer V; Droby A; Steinmetz H; Groppa S; Hattingen E; Deichmann R; Klein JC
    J Magn Reson Imaging; 2016 Dec; 44(6):1600-1607. PubMed ID: 27153293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
    Hojjat SP; Kincal M; Vitorino R; Cantrell CG; Feinstein A; Zhang L; Lee L; O'Connor P; Carroll TJ; Aviv RI
    AJNR Am J Neuroradiol; 2016 Aug; 37(8):1454-61. PubMed ID: 27012299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.
    Ge Y; Grossman RI; Udupa JK; Fulton J; Constantinescu CS; Gonzales-Scarano F; Babb JS; Mannon LJ; Kolson DL; Cohen JA
    Neurology; 2000 Feb; 54(4):813-7. PubMed ID: 10690968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.
    Yaldizli Ö; Pardini M; Sethi V; Muhlert N; Liu Z; Tozer DJ; Samson RS; Wheeler-Kingshott CA; Yousry TA; Miller DH; Chard DT
    Mult Scler; 2016 Feb; 22(2):150-9. PubMed ID: 26014608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilepsy in multiple sclerosis: The role of temporal lobe damage.
    Calabrese M; Castellaro M; Bertoldo A; De Luca A; Pizzini FB; Ricciardi GK; Pitteri M; Zimatore S; Magliozzi R; Benedetti MD; Manganotti P; Montemezzi S; Reynolds R; Gajofatto A; Monaco S
    Mult Scler; 2017 Mar; 23(3):473-482. PubMed ID: 27260699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative T
    Harper JG; York EN; Meijboom R; Kampaite A; Thrippleton MJ; Kearns PKA; Valdés Hernández MDC; Chandran S; Waldman AD;
    Eur Radiol; 2024 Jun; 34(6):3826-3839. PubMed ID: 37943312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
    J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.
    Calabrese M; Reynolds R; Magliozzi R; Castellaro M; Morra A; Scalfari A; Farina G; Romualdi C; Gajofatto A; Pitteri M; Benedetti MD; Monaco S
    PLoS One; 2015; 10(8):e0135428. PubMed ID: 26267665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.